Burkitt's lymphoma and previous AIDS-defining illnesses are not prognostic factors in AIDS-related non-Hodgkin's lymphoma [3]

Journal of Clinical Oncology

Volumn 23, Issue 33, 2005, Pages 8538-8540

  Stebbing, Justin ^a   Mandalia, Sundhiya ^a   Palmieri, Carlo ^a   Nelson, Mark ^a   Gazzard, Brian ^a   Bower, Mark ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LACTATE DEHYDROGENASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER MORTALITY; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK FACTOR; COHORT ANALYSIS; MORTALITY; NOTE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE; UNITED KINGDOM;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BURKITT LYMPHOMA; COHORT STUDIES; GREAT BRITAIN; HUMANS; LYMPHOMA, AIDS-RELATED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 33644687784     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.9512     Document Type: Letter

References (10)

1. Lim ST, Karim R, Nathwani BN, et al: AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: Significant differences in survival with standard chemotherapy. J Clin Oncol 23:4430-4438, 2005
2. Bower M, Gazzard B, Mandalia S, et al: A prognostic index for systemic AIDS-related lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med 143:265-273, 2005
3. Kocks C, Rajewsky K: Stable expression and somatic hypermutation of antibody V regions in B-cell developmental pathways. Annu Rev Immunol 7:537-559, 1989
4. Klein U, Klein G, Ehlin-Henriksson B, et al: Burkitt's lymphoma is a malignancy of mature B cells expressing somatically mutated V region genes. Mol Med 1:495-505, 1995
5. Brezinschek HP, Foster SJ, Brezmschek RI, et al: Analysis of the human VH gene repertoire: Differential effects of selection and somatic hypermutation on human peripheral CD5(+)/IgM+ and CD5(-)/IgM+ B cells. J Clin Invest 99:2488-2501, 1997
6. Liu YJ, Joshua DE, Williams GT, et al: Mechanism of antigen-driven selection in germinal centres. Nature 342:929-931, 1989
7. Bellan C, Lazzi S, Hummel M, et al: Immunoglobulin gene analysis reveals two distinct cells of origin for EBV positive and EBV negative Burkitt's lymphomas. Blood 106:1031-1036, 2005
8. Zhu D, Qi CF, Morse HC 3rd, et al: Deregulated expression of the Myc cellular oncogene drives development of mouse "Burkitt-like" lymphomas from naive B cells. Blood 105:2135-2137, 2005
9. Lane HC, Masur H, Edgar LC, et al: Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 309:453-458, 1983
10. Stebbing J, Gazzard B, Douek DC: Where does HIV live? N Engl J Med 350:1872-1880, 2004